The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A
Open accessAbstract
BACKGROUND: Adeno-associated virus (AAV)-mediated gene therapy is under investigation as a therapeutic option for persons with hemophilia A. Efficacy and safety data include 3 years of follow-up after a single administration of AAV5-hFVIII-SQ. METHODS: We report durable efficacy, long-term safety, and clinical and biologic results in 15 adults with severe hemophilia A (factor VIII level, ≤1 IU per deciliter) who had received a single infusion of AAV5-hFVIII-SQ at various dose levels. We evaluated the factor VIII level, annualized rate of bleeding events, use of factor VIII, safety, expression kinetics, and biologic markers of AAV transduction for up to 3 years. RESULTS: vg per kilogram) had a median factor VIII expression of 13 IU per deciliter; the median annualized rate of bleeding events was 0, and the median use of factor VIII was reduced from 155.5 infusions to 0.5 infusions per year. Bleeding in target joints resolved in five of six participants. The factor VIII pharmacodynamic profiles reflected cellular turnover in the blood and molecular events leading to episomal DNA stabilization for persistent expression, findings that are consistent with previous observations in two model systems. Transgene-derived human factor VIII (hFVIII) protein activity mirrored native hFVIII in hemostatic ability. No inhibitor development, thromboses, deaths, or persistent changes in liver-function tests were observed. CONCLUSIONS: vg per kilogram of the gene therapy. (Funded by BioMarin Pharmaceutical; ClinicalTrials.gov number, NCT02576795; EudraCT number, 2014-003880-38.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Approximately 5 subjects across 3 trials experienced self-limited, vector-infusion reactions at doses of 2 × 1012−6 × 1013 vg/kg, characterized by fever, myalgias, and/or hypotension, which appear consistent with an innate immune response.141,150,152”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [150]
In the citing paper
“multiple HA and HB trials have demonstrated ≥10-fold variability in FVIII:C/FIX:C with the same vector and dose (Harrington et al., 2020, WFH Virtual Summit, conference).145,149,150,153”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [150]
In the citing paper
“Corticosteroids are the most commonly used agents to resolve transaminitis, however, its relationship with resolution by corticosteroids and T-cell response are not always clear as observed in a hemophilia A trial (28, 105).”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [105]
Citations
Cites
Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy
Mendell, J. R., Al-Zaidy, S., Shell, R., Arnold, W. D., Rodino-Klapac, L. R., Prior, T. W., Lowes, L., Alfano, L., Berry, K., Church, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706198 · Cited by 2,381
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Self-citationAnalysis of AAV Serotypes 1–9 Mediated Gene Expression and Tropism in Mice After Systemic Injection
Zincarelli, C., Soltys, S., Rengo, G., & Rabinowitz, J. E. (2008) · Molecular Therapy · doi:10.1038/mt.2008.76 · Cited by 1,490
Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B
Nathwani, A. C., Reiss, U. M., Tuddenham, E. G. D., Rosales, C., Chowdary, P., McIntosh, J., Della Peruta, M., Lheriteau, E., Patel, N., Raj, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407309 · Cited by 1,273
Self-citationEffect of genome size on AAV vector packaging
Wu, Z., Yang, H., & Colosi, P. (2010) · Molecular Therapy · doi:10.1038/mt.2009.255 · Cited by 1,029
Definitions in hemophilia: communication from the SSC of the ISTH
Blanchette, V. S., Key, N. S., Ljung, L. R., Manco‐Johnson, M. J., van den Berg, H. M., & Srivastava, A. (2014) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12672 · Cited by 761
Nucleotide sequence and organization of the adeno-associated virus 2 genome
Srivastava, A., Lusby, E. W., & Berns, K. I. (1983) · Journal of Virology · doi:10.1128/jvi.45.2.555-564.1983 · Cited by 721
AAV5–Factor VIII Gene Transfer in Severe Hemophilia A
Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G. F., Wong, W. Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708483 · Cited by 694
Self-citationAntioxidants reduce endoplasmic reticulum stress and improve protein secretion
Malhotra, J. D., Miao, H., Zhang, K., Wolfson, A., Pennathur, S., Pipe, S. W., & Kaufman, R. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809677105 · Cited by 673
Nakai, H., Yant, S. R., Storm, T. A., Fuess, S., Meuse, L., & Kay, M. A. (2001) · Journal of Virology · doi:10.1128/jvi.75.15.6969-6976.2001 · Cited by 478
Research works printed but not linked: 2
- Torres R, Patton K, Holcomb J, Zoog S, Russell C, Vettermann C. Characterization of AAV5-FVIII-SQ vector DNA in human blood by real-time and Droplet Digital PCR. Mol Ther 2019;27(4):Suppl 1:436-436.
- Fong S, Handyside B, Sihn C-R, et al. The potential for induction of ER stress response by an AAV5-based construct of B-domain deleted FVIII is dependent on the strength of the hepatic specific promoter. Mol Ther 2018;26(5):Suppl 1:375-376.
Cited by
Items 401–453 of 453
Development, market authorization and market access of gene and cell-based therapies
ten Ham, R. M. T. (2021) · Utrecht University Repository (Utrecht University) · doi:10.33540/612
Rare disease registries: a must for regulatory decision making
van Ek, C. J. J. E. V. (2022) · Utrecht University Repository (Utrecht University) · doi:10.33540/1095
Positioning of non-factor replacement therapy in the hemophilia treatment
Sakai, M. (2022) · Japanese Journal of Thrombosis and Hemostasis · doi:10.2491/jjsth.33.37
Inhibitors and immune tolerance induction in hemophilia A: A balancing act
Schep, S. J. (2022) · Utrecht University Repository (Utrecht University) · doi:10.33540/868
Delivery and Formulation Methods for Therapeutic Genome Editing
Blenke, E. O., & Krishnamurthy, V. R. (2022) · Wiley eBooks · doi:10.1002/9781119671404.ch18
Gene Therapy for Congenital Hearing Loss
Timashpolsky, A., Chorney, S. R., & O’Reilly, R. (2022) · Current Otorhinolaryngology Reports · doi:10.1007/s40136-022-00427-0
Gene Therapy in Haemophilia: Updates from Clinical Trials and Insights to Future Technologies
Carter, S. (2022) · EMJ Cardiology · doi:10.33590/emjcardiol/10136425
Gene and Cell Therapy: How to Build a BioDrug
Baumeister, S. H. C., & Woolfrey, A. E. (2022) · Pediatric oncology · doi:10.1007/978-3-031-06357-2_6
Impact of Emicizumab on Hemophilia Management
Shimozawa, K. (2023) · Journal of Nihon University Medical Association · doi:10.4264/numa.82.1_23
Dorofieieva, V. R., & Fedota, O. (2022) · The Journal of V N Karazin Kharkiv National University series Medicine · doi:10.26565/2313-6693-2022-45-03
(2022) · The Journal of V N Karazin Kharkiv National University series Medicine · doi:10.26565/2313-6693-2022-45
Gene Therapy and Therapeutic Genome Editing in Liver for Lipid Disorders
Rader, D. J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00030-3
Gutensohn, K. (2023) · Trillium Diagnostik · doi:10.47184/td.2023.02.04
Diagnosis and Management of Heart Failure in Children
Rossano, J. W., Lin, K. Y., & Edwards, J. J. (2023) · Springer eBooks · doi:10.1007/978-3-030-42937-9_80-1
Terapia Génica como Tratamiento para la Hemofilia
Cedillo-Prado, J., & Córdova-Serrano, R. (2023) · 593 Digital Publisher CEIT · doi:10.33386/593dp.2023.5.1978 · Cited by 1
Genome Integration of Adeno-associated Virus (AAV) Vectors into Infected Cells
Hirai, Y. (2023) · Nihon Ika Daigaku Igakkai Zasshi · doi:10.1272/manms.19.211
Breakthrough Study Develops Potential Cure for Hemophilia A
Cole, E. (2023) · Qapsule Queen s Undergraduate Health Sciences Journal · doi:10.24908/qap.v1i1.16374
Molecular diagnostics for coagulopathies
Smolkin, M. B., & Shmookler, A. D. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-822824-1.00028-6
Braun, M., & Sun, K. (2024) · Wiley eBooks · doi:10.1002/9781119852810.ch4
AAV delivers as a lingering guest, not an invader
Almeida-Porada, G. D. (2024) · Blood · doi:10.1182/blood.2024024506
Diagnosis and Management of Heart Failure in Children
Rossano, J. W., Lin, K. Y., & Edwards, J. J. (2024) · Springer eBooks · doi:10.1007/978-3-031-07563-6_80
Genetic Characterization of the Factor VIII Gene
Villadiego, A. M., & Doncel, S. S. (2025) · IntechOpen eBooks · doi:10.5772/intechopen.1009259
Agachi, D., Ţurea, V., & Eșanu, G. (2025) · Moldovan Journal of Health Sciences · doi:10.52645/mjhs.2025.1.01
Olson, S. R., & Kumar, R. (2022) · doi:10.1182/ashsap8.chapter10
Sustained high expression of human FVII following AAV8-mediated gene delivery in mice
D’Amico, A., Blits, B., van den Herik, J., de Winter, F., Kaijen, P. H. P., Hobo, B., van Asbeck, A. H., Verhaagen, J., Mosmuller, D. G. M., & Voorberg, J. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101523
AAV9-mediated gene therapy restores liver function in the MEGDHEL mouse model
Wei, T., Lin, Y., Ouyang, W., Yu, L., Yang, X., Chen, L., He, X., Fang, Q., Zheng, X., Tong, H., et al. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2025.120014
Structure, Function, and Clinical Relevance of Molecular Chaperones – A Review Article
Al-Khafaji, S. M., Al-sallami, M. H., General Directorate of Education in Alnajaf, M. O. E., & Al-fahham, A. A. (2025) · International Journal of Medical Science and Dental Health · doi:10.55640/ijmsdh-11-07-13
Genetic Engineering in Medicine: New Tools and Medical Applications
Al-janabi, A. M., Alshamarti, I., & Al-fahham, A. A. (2025) · International Journal of Medical Science and Dental Health · doi:10.55640/ijmsdh-11-07-15
A Paradigm Shift in Hemophilia Care: The Promise of Gene Therapy
Pasha, S. F. A., Anver, T. F. K., & Srinivasamurthy, S. K. (2025) · Current Gene Therapy · doi:10.2174/0115665232389378250727013548 · Cited by 2
A battery-free, chipless, soft nanofluidic intracellular delivery patch for internal organsPreprint
Yu, C., Li, M., Chang, L., Yu, X., Yin, D., Wang, P., Hao, Y., Yue, W., Yao, K., Wang, Y., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-2154899/v1
Self-citationGong, J., Yang, R., Zhou, M., & Chang, L.-J. (2023) · Figshare · doi:10.6084/m9.figshare.23504967
Ng, R. C.-L., Jian, M., Ma, O. K.-F., Xiang, A. W., Bunting, M., Kwan, J., Wong, C. W.-K., Yick, L.-W., Chung, S. K., Lam, K. S. L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26698709
Gong, J., Yang, R., Zhou, M., & Chang, L.-J. (2023) · Figshare · doi:10.6084/m9.figshare.23504970
Yu, H., Schroeder, J. A., Mattson, J. G., Gao, C., & Shi, Q. (2026) · Blood Advances · doi:10.1182/bloodadvances.2025017921
Exploring gene editing as a potential therapeutic strategy for hemophilia
Kumarasamy, N., & Balakrishnan, B. (2026) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2026.1727204
Cugno, M., & Mannucci, P. M. (2026) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2026.103456
Guo, Y., Huang, J., Zhang, Y., Huang, Y., Li, Z., Xie, Y., Cao, Y., Qian, K., Bai, F., Li, W., et al. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.04.001
Final Analysis of the Phase 1/2 Trial of Valoctocogene Roxaparvovec for Severe Haemophilia A
Raheja, P., Rangarajan, S., Lester, W., Madan, B., Pierce, G. F., Symington, E. M., Millar, C. M., Osmond, D., Li, M., & Chavele, K.-M. (2026) · Haemophilia · doi:10.1111/hae.70284
Self-citationFrom early promise to market withdrawal of valoctocogene roxaparvovec
Pierce, G. F. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.04.005
Self-citationLa thérapie génique dans l’hémophilie
Rauch, A. (2026) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2026.02.012
Genetic abnormalities in glomerular function
Hurcombe, J., & Coward, R. J. M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-12-815389-5.00072-1
Italian Patients Journey for Gene Therapy in Haemophilia A
Minno, G. D., Spadarella, G., Borchiellini, A., Borrelli, A., Buzzi, A., Castaman, G., Cecchi, M., CRISTOFARO, R. D., Mura, V. L., Lupi, A., et al. (2026) · Haemophilia · doi:10.1111/hae.70332
Vicidomini, A., Boisgérault, F., Romano, G., Guarnaccia, C., Vidal, P., Collaud, F., Soria, L. R., Sabbata, G. D., Tedesco, N., Lisjak, M., et al. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201793
Regulatory and CMC Strategies for Gene and Cell Therapies: Global Perspectives
Kothari, K., Nayak, S., Shah, S., Patel, D., Madhukar, N., & Dave, P. (2024) · Journal of Biomedical and Pharmaceutical Research · doi:10.32553/jbpr.v13i4.1488
Analysis of mechanisms increasing the risk of inhibitor development in hemophilia A treatment
Lubkowska, A., Paczkowska, A., Kempińska‐Podhorodecka, A., & Urasiński, T. (2026) · Acta Haematologica Polonica · doi:10.5603/ahp.111944
Comprehensive Management of Hemophilia, Including Recent Therapeutic Advances
Chakrabarti, P., & Pandharipande, A. S. (2026) · Springer eBooks · doi:10.1007/978-981-92-1167-8_19
Five-year durability in cell and gene therapy: evidence review and implications for payer coverage
Pittos, E. C., & DePinto, J. (2026) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2026.2723931
Gene Therapy Approaches for the Treatment of Phenylketonuria
Martinez, M. A., Young, L. J., Harding, C. O., Schwank, G., & Thöny, B. (2026) · Springer eBooks · doi:10.1007/978-3-032-26690-3_20
Wu, K., Zhao, L., Yu, Z., & Guo, J. J. (2026) · Injury · doi:10.1016/j.injury.2026.113667
Transthyretin Amyloidosis: From Mechanisms to Treatment
Triposkiadis, F., Andrew, X., Georghiou, G. P., Stephanou, A., & Patrikios, I. S. (2026) · Biomolecules · doi:10.3390/biom16101401
Long-term safety of treatment of hemophilia A: a comprehensive review
Mahlangu, J. N. (2026) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2026.2742174
Hemophilia: Carrier testing and therapy
Hemaliya, C., Singh, A. K., Meena, L. P., Kumar, A., & Ali, A. (2026) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_1420_25
Mahlangu, J. N. (2026) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2026.2754085
Metadata
- Authors
- Pasi, K. J., Rangarajan, S., Mitchell, N., Lester, W., Symington, E., Madan, B., Laffan, M., Russell, C. B., Li, M., Pierce, G. F., & Wong, W. Y.
- Affiliations
- From Barts and the London School of Medicine and Dentistry (K.J.P.), Guy’s and St. Thomas’ NHS Foundation Trust (B.M.), and the Centre for Haematology, Imperial College London (M. Laffan), London, University Hospital Southampton, Southampton (S.R.), University Hospitals Birmingham NHS Foundation Trust, Birmingham (W.L.), and Cambridge University Hospitals NHS Foundation Trust, Cambridge (E.S.) — all in the United Kingdom; and BioMarin Pharmaceutical, Novato (N.M., C.B.R., M. Li, W.Y.W.), and private...
- University Hospitals Birmingham NHS Foundation Trust (GB)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-01-02
- Volume
- 382
- Issue
- 1
- Pages
- 29-40
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2998050720
- Cited by
- 448
- References
- 29
- Citations by year
- 2026: 30 · 2025: 52 · 2024: 59 · 2023: 67 · 2022: 96 · 2021: 71 · 2020: 73
- FWCI
- 48.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- Queen Mary Research Online (Queen Mary University of London) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Funders
- BioMarin Pharmaceutical
- Topics
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Keywords
- hemophilia A, adeno-associated virus gene therapy, factor VIII, long-term safety, annualized bleeding rate, transgene expression kinetics
- MeSH terms
- Dependovirus, Adult, Coagulants, Factor VIII, Follow-Up Studies, Genetic Vectors, Hemophilia A, Hemorrhage, Humans, Infusions, Intravenous, Male, Middle Aged, Genetic Therapy, Biomarkers, Transgenes, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.